Jacobs Levy Equity Management, Inc Pacira Bio Sciences, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q1 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 855,488 shares of PCRX stock, worth $19.3 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
855,488
Previous 454,261
88.33%
Holding current value
$19.3 Million
Previous $8.56 Million
148.4%
% of portfolio
0.09%
Previous 0.03%
Shares
14 transactions
Others Institutions Holding PCRX
# of Institutions
256Shares Held
50.9MCall Options Held
157KPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$181 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.24MShares$118 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$51.1 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.24MShares$50.5 Million0.09% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.05MShares$46.2 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.03B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...